ストックスクリーナーアプリを入手
2.80
6.98%
-0.21
アフターアワーズ：
2.82
0.02
+0.71%
Cabaletta Bio Inc (CABA) 最新ニュース
CABA - Finviz
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Business Wire
CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption - TradingView
CABA: Rese-cel shows durable, safe, drug-free responses, enabling rapid outpatient adoption and expansion - TradingView
Cabaletta Bio Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
CABALETTA BIO INC (CABA) Stock Chart - ChartMill
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa
CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com India
Cabaletta Bio reports phase 1/2 data for autoimmune therapy By Investing.com - Investing.com Nigeria
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The Manila Times
Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await - Bez Kabli
Cabaletta Bio (CABA) Climbs 2.7% as Biotech Stock Tests Key Resistance Near $4.14Low Risk Entry Stocks - thelegaladvocate.com
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
CABA Technical Analysis | Trend, Signals & Chart Patterns | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
CABA stock on track for best day in 6 months after positive early results from cell therapy trial - MSN
Cabaletta Reports Drug-Free Responses in CAR-T Study - MyChesCo
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView
CABA Shows Promising Results in New Clinical Data - GuruFocus
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):